Who Generates More Revenue? Eli Lilly and Company or Telix Pharmaceuticals Limited

Eli Lilly's revenue dominance over Telix Pharmaceuticals.

__timestampEli Lilly and CompanyTelix Pharmaceuticals Limited
Wednesday, January 1, 20141961560000028336824
Thursday, January 1, 20151995870000032319194
Friday, January 1, 20162122210000029404631
Sunday, January 1, 20172287130000031769230
Monday, January 1, 20182149330000020439380
Tuesday, January 1, 20192231950000024186536
Wednesday, January 1, 2020245398000004680000
Friday, January 1, 2021283184000004898000
Saturday, January 1, 202228541400000155984000
Sunday, January 1, 202334124100000496659000
Monday, January 1, 202445042700000
Loading chart...

Infusing magic into the data realm

Revenue Race: Eli Lilly vs. Telix Pharmaceuticals

In the competitive landscape of pharmaceuticals, revenue generation is a key indicator of success. Over the past decade, Eli Lilly and Company has consistently outperformed Telix Pharmaceuticals Limited in terms of revenue. From 2014 to 2023, Eli Lilly's revenue surged by approximately 74%, reaching a peak in 2023. In contrast, Telix Pharmaceuticals, while showing growth, remains a smaller player, with its revenue in 2023 being just a fraction of Eli Lilly's.

Eli Lilly's robust growth can be attributed to its strategic investments in research and development, leading to successful product launches. Meanwhile, Telix, a relatively newer entrant, is carving its niche in the radiopharmaceuticals market. As the industry evolves, it will be intriguing to see how these companies adapt and compete. This data not only highlights the current standings but also sets the stage for future developments in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025